Replies to post #232 on RegeneRx Biopharmaceuticals Inc (RGRX)

[Saltlyfe]

The ARISE-2 study, which was conducted together with Ora, Inc., demonstrated a number of statistically significant improvements in both signs and symptoms of dry eye syndrome with 0.1% RGN-259 versus placebo, while showing excellent safety, comfort, and tolerability profiles. The ocular discomfort symptom showed a statistically significant reduction in the RGN-259-treated group at day 15 as compared to placebo (p=0.0149) in the change from baseline. For sign, RGN-259 also improved the dry eye

Stubborn I think we are about to make some money here. IMO.
Just duplicating the above Arise 2. Lots of big money behind the scene here.
Arise 3 is well underway.


Enjoy the ride.